
|Articles|March 31, 2023
Recommendations for Accelerating Cell and Gene Therapies
Author(s)Cognizant
While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference
2
JP Morgan 2026: Novavax Shifting Towards Partnership-Driven Strategy
3
JP Morgan 2026: AbbVie Advances its Pipeline
4
JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success
5